离体肝切除联合自体肝移植在晚期泡型肝包虫病中的应用研究

注册号:

Registration number:

ChiCTR-ONC-17013594 

最近更新日期:

Date of Last Refreshed on:

2017-11-29 13:08:39 

注册时间:

Date of Registration:

2017-11-29 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

离体肝切除联合自体肝移植在晚期泡型肝包虫病中的应用研究

Public title:

The research on the application of ex vivo resection combined with autotransplantation in treating end-stage alveolar echnococcosis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

离体肝切除联合自体肝移植在晚期泡型肝包虫病中的应用研究

Scientific title:

The research on the application of ex vivo resection combined with autotransplantation in treating end-stage alveolar echnococcosis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

孔俊杰 

研究负责人:

王文涛 

Applicant:

Kong Junjie 

Study leader:

Wang Wentao 

申请注册联系人电话:

Applicant telephone:

+86 18769788726

研究负责人电话:

Study leader's
telephone:

+86 18980601895

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1534759354@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wwt02@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川省成都市武侯区人民南路3段17号

研究负责人通讯地址:

四川省成都市武侯区国学巷37号

Applicant address:

17 Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, China

Study leader's address:

17 Section 3, Renmin Road South, Wuhou District, Chengdu, Sichuan, China

申请注册联系人邮政编码:

Applicant postcode:

610041

研究负责人邮政编码:

Study leader's postcode:

610041

申请人所在单位:

四川大学华西临床医学院

Applicant's institution:

West China School of Medicine, Sichuan University

研究负责人所在单位:

四川大学华西医院肝脏外科

Affiliation of the Leader:

Department of Liver Surgery, West China Hospital of Sichuan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2017-38

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理分委会

Name of the ethic committee:

West China Hospital of Sichuan University Biomedical Research Ethics Committe

伦理委员会批准日期:

Date of approved by ethic committee:

2017-05-04 00:00:00

伦理委员会联系人:

曾勇

Contact Name of the ethic committee:

Zeng Yong

伦理委员会联系地址:

四川省成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue Xiang, Wuhou District, Chengdu, Sichuan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院肝脏外科

Primary sponsor:

Department of Liver Surgery, West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川省成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Xiang, Wuhou District, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

四川省成都市武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

37 Guoxue Xiang, Wuhou District, Chengdu, Sichuan, China

经费或物资来源:

四川大学华西医院临床诊疗新技术、新项目

Source(s) of funding:

New Medical Technology Foundation of West China Hospital of Sichuan University

研究疾病:

泡型包虫病  

Target disease:

Alveolar Echinococcosis

研究疾病代码:

B67.7

Target disease code:

B67.7

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

通过对全离体肝切除联合自体余肝移植、半离体肝切除联合自体余肝移植、异体肝移植、常规肝切除治疗晚期肝包虫病进行比较,探讨全离体和半离体自体移植的适应症,下腔静脉的不同重建方式及不同重建材料,第一肝门受侵犯的三级肝门重建方式,长时间肝脏离体后无肝期病人安全监控问题,术前肝功能评价和余肝容积计算和肝内重要管道受侵犯评估,评价上述四种疗法的近期及远期并发症及生存率。  

Objectives of Study:

By comparing ex vivo liver resection and autotransplantation, ex situ liver resection and autotransplantation,Liver transplantation and Radical resection in treating end-stage hepatic alveolar echinococcosis, our aim is to find the indications of ex vivo liver resection and autotransplantation and ex situ liver resection and autotransplantation, the different ways and materials of inferior vena cava reconstruction, the way to reconstruct tertiary portal hilum, the solution to monitor safety of patients during long-term anhepatic period, the way to do preoperative evaluation, calculate remanent liver volume and assess the invasion of intrahepatic conduits, and evaluate the short-term and long-term complications and overall survival of the four treatments.

药物成份或治疗方案详述:

无 

Description for medicine or protocol of treatment in detail:

None 

纳入标准:

Inclusion criteria

排除标准:

1.不符合纳入标准的患者;
2.拒绝签署知情同意书者;
3.术前评估认为无法手术治疗者;
4.妊娠或哺乳期妇女;
5.依从性较差者。

Exclusion criteria:

1. patients who do not meet the inclusion criteria;
2. patients who redused to sign informed consent file;
3. patients who can't tolerate the surgery;
4. pregnancy, breastfeeding women;
5. patients who have poor compliance.

研究实施时间:

Study execute time:

From 2012-01-01 00:00:00 To 2019-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2012-01-01 00:00:00 To 2019-01-01 00:00:00

干预措施:

Interventions:

组别:

全离体肝切除联合自体余肝移植组

样本量:

60

Group:

group of ex vivo liver resection and autotransplantation

Sample size:

干预措施:

全离体肝切除联合自体余肝移植

干预措施代码:

Intervention:

ex vivo liver resection and autotransplantation

Intervention code:

组别:

半离体肝切除联合自体余肝移植组

样本量:

10

Group:

Group of ex situ liver resection and autotransplantation

Sample size:

干预措施:

半离体肝切除联合自体余肝移植

干预措施代码:

Intervention:

ex situ liver resection and autotransplantation

Intervention code:

组别:

异体肝移植组

样本量:

10

Group:

Group of liver transplantation

Sample size:

干预措施:

异体肝移植

干预措施代码:

Intervention:

Liver transplantation

Intervention code:

组别:

常规肝切除组

样本量:

420

Group:

Group of radical resection

Sample size:

干预措施:

常规肝切除

干预措施代码:

Intervention:

Radical resection

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川省 

市(区县):

成都市 

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院 

单位级别:

三甲 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary Hospital

测量指标:

Outcomes:

指标中文名:

生存率

指标类型:

主要指标

Outcome:

Overall survival

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

复发率

指标类型:

主要指标

Outcome:

Recurrence rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

ICU住院时间

指标类型:

次要指标

Outcome:

Staying time in ICU

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总住院时间

指标类型:

次要指标

Outcome:

Total hospital stays

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

住院花费

指标类型:

次要指标

Outcome:

Cost of treatment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症发生率

指标类型:

次要指标

Outcome:

Incidence of complication

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活质量

指标类型:

次要指标

Outcome:

Quality of life

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

泡型包虫标本

组织:

肝脏

Sample Name:

Specimens of Alveolar Echinococcosis

Tissue:

Liver

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 70 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

-

Blinding:

-

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验结束后,通过论文形式公开,通过文献索引搜索

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

terminal of this study, pubication by the form of articles, access the data through the paper index

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集有参与研究人员进行密切分工协作;数据的整理和汇总则有项目负责人进行,所有过程均采用HIS系统或者EXCEL文件进行。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection involves close division of work among researchers. Data arrangement and general arrangement are carried out by project managers and all processes are carried out using HIS system or EXCEL files.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2017-11-29 13:08:39